



















Testing Hair for Fentanyl Exposure: A Method to 
 

























Background: Deaths from fentanyl exposure continue to increase in the US. Fentanyl test strips 
are now available to test urine for presence of fentanyl, but additional testing methods are 
needed to determine past exposure and to determine exposure to specific analogs.  
Objectives: To investigate exposure to such analogs through hair-testing. Methods: 40 
individuals in inpatient detoxification (7.5% female) reporting past-month heroin use  were 
surveyed and provided a hair sample to be tested at a later date. While results could not be 
provided to patients, they were asked how they would respond if informed that their hair 
tested positive for fentanyl. UHPLC-MS/MS was used to test for past exposure to fentanyl and 
six other novel synthetic opioids and fentanyl biomarkers/metabolites.  
Results: 27.5% reported known fentanyl use in the past year and 67.5% reported suspected 
exposure. 97.5% (39 of 40) tested positive for fentanyl, 90.0% tested positive 4-ANPP (a 
biomarker) and norfentanyl (a metabolite); 82.5% tested positive for acetyl-fentanyl, 47.5% 
tested positive for furanyl-fentanyl, and 7.5% tested positive for U-47700. Most participants 
(82.5%) reported they would warn others about fentanyl if they learned their hair tested 
positive; 75.0% reported they would try to stop using heroin, and 65.0% reported they would 
ensure that someone nearby has naloxone to reverse a potential overdose.  
Conclusions: Hair testing is useful in detecting the past exposure to fentanyl, its analogs, and 
other novel synthetic opioids. Further research is needed to determine whether individuals 
who use heroin learning about exposure affects drug-taking and treatment-seeking behavior. 
 




Deaths related to use of fentanyl, its analogs, and novel synthetic opioids have more 
than doubled in the US from 9,580 in 2015 to 19,413 in 2016 (1). In 2016, fentanyl and/or its 
analogs were detected in almost half (46%) of opioid-related decedents (1). Fentanyl, a 
synthetic opioid, is 50-100 times more potent than morphine, and many of its analogs are 
thousands of times more potent than morphine (2,3). These compounds are increasingly 
adulterating heroin, often unbeknownst to individuals who use, increasing risk of overdose (4). 
Studies suggest many individuals who misuse opioids are concerned about unintentional 
exposure to fentanyl, although some individuals who use heroin seek out fentanyl.  For 
example, one study found that 18% of homeless or marginally housed individuals who use 
opioids and tested positive for fentanyl reported known use (5). Studies of individuals who use 
drugs have found that 85-92% wanted to know if their drugs contain fentanyl (6,7). Thus, more 
research is needed not only to test for exposure to these compounds, but also to determine 
how individuals who use drugs  learning about exposure may affect their drug-taking (e.g., 
harm reduction) and treatment-seeking behavior.  
As the opioid crisis continues to worsen in the US, national and state-level statistics 
continue to focus largely on seizures, poisonings, and deaths related to exposure to fentanyl 
and its analogs (1,8,9). However, literature suggests variable awareness regarding the extent to 
which individuals who use heroin are aware of potential exposure to fentanyl (5,10-15). A new 
common method of determining recent exposure to fentanyl or its analogs is through urine 
testing (5). BTNX fentanyl test strips, for example, can rapidly detect fentanyl and many of its 
analogs in urine (5,7). However, such test strips cannot distinguish between fentanyl and its 
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analogs or extent of exposure. Urine testing is also limited by the persistence of compounds 
being detectable for only ~3 days (16). Research utilizing fentanyl test strips to test urine (or to 
directly test drug samples) is in its infancy, and many clinicians do not routinely utilize fentanyl 
strips to test their patients.  
While urine and drug sample testing for presence of fentanyl can provide useful 
information regarding recent exposure, additional testing methods are needed to help address 
limitations of urine and drug sample-testing. Our past work has determined that hair testing is 
an optimal biological matrix to obtain an extensive exposure history of past use of novel 
psychoactive substances (17-20). Although hair testing cannot detect very recent exposure 
(e.g., within a few days post-use) or yield immediate results, it allows wide-range monitoring of 
drug exposure over extended periods of time. Acquiring a more extensive history of exposure 
may be useful in informing prevention or harm reduction among individuals who use heroin or 
other drugs with potential for fentanyl adulteration.   
Past exposure to fentanyl, its analogs, and other novel synthetic opioids was examined 
in a sample of individuals who recently used heroin. Beliefs and concerns about fentanyl were 
assessed and participants were asked how they would respond if they learned their hair had 
tested positive for fentanyl. Results will inform prevention and harm reduction among 
individuals who use drugs who are at risk for fentanyl exposure.    
 
Methods 
Participants and Procedure 
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 Inpatients were recruited from the detoxification unit at Bellevue Hospital Center, 
a university-affiliated, public sector hospital in New York City. Patients were recruited from 
April through July of 2018. Individuals were approached by a research assistant within the 
inpatient unit to determine eligibility and interest in participation. To be eligible, inpatients had 
to 1) be at least 18 years of age, 2) report using heroin in the past 30 days, and 3) have 
adequate length/amount of hair for analysis (i.e., ~100 hairs, >1cm in length). While head hair 
was preferred, hair from the body (e.g., leg, arm, chest), face (e.g., beard), and pubic region 
were also acceptable. Eligible individuals provided informed consent, completed a brief survey 
on an electronic tablet (which typically took about 10 minutes to complete), and then provided 
a hair sample. A research assistant cut the hair sample with a scissor or buzzer from as close to 
the scalp or skin as possible. In some cases (e.g., for those providing pubic hair), the sample was 
cut by the participant in private upon receiving proper instructions. Participants completing the 
study received a $10 MetroCard. The Institutional Review Boards at New York University 
Langone Medical Center and Bellevue Hospital Center approved all study procedures. The 
response rate for participation was 83% with 40 patients participating in the study. 
 
Measures 
Participants were asked about demographic characteristics including age, race/ethnicity, 
education, income, and employment. With regard to heroin use, they were asked about 
route(s) of administration, whether heroin was used daily, the number of years they have been 
using heroin, and how many bags of heroin they use per day (on average). Participants were 
asked whether they had knowingly used fentanyl in the past 12 months, and they were asked 
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about beliefs and concerns regarding potential fentanyl exposure. Although hair test results 
could not be provided to participants, they were asked whether they agreed with 7 statements 
regarding how they would respond if they learned that fentanyl was detected in their hair 
sample. Statements were based on previous qualitative studies of unintentional fentanyl 
exposure (6, 21, 22), and assessed whether they would 1) warn individuals they know who use 
heroin that they may be unknowingly using fentanyl, 2) try to stop using heroin, 3) use heroin 
more slowly or in smaller amounts, 4) take small test doses to see how they react, 5) make sure 
someone nearby has naloxone to reverse an overdose, 6) find a more trustworthy dealer, and 
7) use drug test strips that can detect fentanyl. 
 
Hair Analysis  
The majority of participants provided hair from their head (57.5%, n=23), followed by 
leg (12.5%, n=5) or arm (12.5%, n=5), the chest (7.5%, n=3), beard (5.0%, n=2), and pubic region 
(5.0%, n=2). Hair was locked in a piece of aluminum foil and placed into a small envelope 
containing the participant’s identification number (to link test results to survey responses at a 
later date). A minimum quantity of 25 mg of hair was needed to perform the analysis. All 
samples were analyzed in their full length. The average length of head hair sample was 4.0 cm 
(median=3.0 cm), where the approximated diagnostic window is based on normal growth rate 
(1 cm=1 month). It was not possible to perform a segmental analysis or to test for other drugs 
(i.e., heroin), due to the low amount of available hair. 
Hair testing was conducted using an on-purpose developed and validated ultra-high 
performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method (20). 
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The target analytes were 1) fentanyl, 2) carfentanil, 3) acetylfentanyl, 4) furanylfentanyl, 5) 
norfentanil, 6) 4-ANPP, and 7) U-47700. 4-ANPP is considered a biomarker of several fentanyl 
analogs, and norfentanil is a metabolite, so these were included in our testing (23). All fentanyl 
analogs and novel opioids examined were currently on the black market in the US (24). The 
parent drug usually represents the target analyte in the keratin matrix that incorporates it from 
sweat and/or bloodstream, the sebum, and/or from external contamination (25). The limits of 
detection (LODs) values were in the range 0.1-0.3 pg/mg for all analytes and the limits of 
quantitation (LOQs) values lied between 0.3-0.9 pg/mg.   
 
Statistical Analysis 
 Hair results were dichotomized into whether or not exposure to each compound was 
detected and merged with participant survey data. Descriptive analyses were conducted to 
describe the participants and test results. Chi-square and Fisher’s Exact Test was used to 
examine whether there were differences between those reporting known fentanyl use vs. no 
known fentanyl use with regard to beliefs and concerns about fentanyl, behavioral aspirations 
related to test results, and testing positive for each separate analog.  
 
Results 
 Table 1 presents the demographic and heroin use characteristics of the 40 participants. 
On average, participants were 41.5 years of age (SD=10.6, range=20-60); 75.0% reported using 
heroin daily, and on average, they had been using heroin for 12.8 (SD=11.7) years, and use 11.4 
(SD=7.3) bags of heroin per day.  
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 Over a quarter (27.5%, n=11) of participants reported that they had knowingly used 
fentanyl within the past year. Table 2 presents descriptive statistics regarding beliefs and 
concerns about fentanyl. Two-thirds (67.5%) of participants reported suspecting they had been 
exposed to fentanyl. 87.5% of participants reported that they would want to know if they had 
been exposed to fentanyl, and about two-thirds (65.0%) reported being very or somewhat 
concerned about fentanyl adulteration. 30.0% reported believing they would be able to notice 
if their heroin contained fentanyl, and almost half (47.5%) reported that they expected their 
hair to test positive for fentanyl. The only significant difference between those reporting known 
use versus unknown use was with regard to expecting hair to test positive for fentanyl. 
Specifically, 90.9% of those reporting known use and 31.0% of those reporting no known use 
expected a positive result (p=.001).  
With regard to how participants felt they would respond if informed their hair tested 
positive for fentanyl (Table 2), 82.5% reported they would warn other individuals who use 
heroin  about fentanyl adulteration; 75.0% reported they would try to stop using heroin, 67.5% 
reported they would use heroin more slowly or in smaller amounts; 67.5% reported they would 
take small tests doses first; 65.0% reported they would ensure that someone nearby has 
naloxone to reverse a potential overdose, 57.5% reported that they would find a more 
trustworthy dealer, and 47.5% reported they would use test strips that can detect fentanyl. No 
significant differences were detected for any of these behavior aspirations between those 
reporting known fentanyl use and those reporting no known use.  
With respect to test results, all but one participant (39 of 40; 97.5%) tested positive for 
fentanyl. 90.0% also tested positive for 4-ANPP and norfentanyl; 82.5% tested positive for 
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acetyl-fentanyl, 47.5% tested positive for furanyl-fentanyl, and 7.5% tested positive for U-
47700. The participant who did not test positive for fentanyl also did not test positive for other 
compounds tested. Of the 39 patients testing positive, 71.8% were patients who denied known 
use. Prevalence of detecting positive for each of these compounds was further compared 
between those reporting known fentanyl use and those reporting no known use (Table 2) and 
no significant differences were detected. Figure 1a depicts the distributions of number of 
compounds detected according to whether known fentanyl use was reported and Figure 1b 
depicts the specific compounds detected for all participants and according to whether known 
fentanyl use was reported. Only five (12.8%) of those testing positive for fentanyl did not also 
test positive for at least one analog. Among those testing positive for fentanyl, 38.5% (n=15) 
tested positive for one analog, 43.6% (n=17) tested positive for two other analogs (with one 
testing positive for one analog and U-47700), and 5.1% (n=2) tested positive for two analogs 
and also tested positive for U-47700. 
Table 3 presents concentrations of analogs detected in each patient for descriptive 
purposes. Fentanyl concentrations were in the range 2.3-8600 pg/mg (mean=860 pg/mg, 
median=440 pg/mg). Acetylfentanyl concentrations were in the range 2.1-3200 pg/mg 
(mean=160 pg/mg, median=26 pg/mg). Furanylfentanyl concentrations were in the range 0.7-
42 pg/mg (mean=8.0 pg/mg, median=1.6 pg/mg). In three samples, U-47700 was detected at 





 To our knowledge, this is the first study to examine (unknown) exposure to fentanyl in 
individuals who use heroin via hair testing. Alarmingly, 98% of this sample (71.8% of whom 
denied known use) tested positive for fentanyl. Likewise, 85% of participants tested positive for 
one or more fentanyl analog and 7.5% tested positive for the novel synthetic opioid U-47700, 
suggesting exposure to more than one analog is common. Since hair analysis gives evidence of 
the cumulated incorporation into the matrix of the substances consumed over an extended 
period of time, it is difficult to speculate if fentanyl and its analogs were taken alone or 
simultaneously, and whether one analog (e.g., acetylfentanyl) was present as an impurity of the 
fentanyl.  
Incidence of unknown fentanyl exposure in this study was higher than in recent 
fentanyl-testing studies. For example, a recent study of a sample of individuals in Canada who 
use drugs found that three-quarters (75%) of those reporting nonmedical opioid use and 
denying fentanyl use had their urine test positive for fentanyl (5). In a recent study of inpatients 
seeking opioid withdrawal management, of those denying known exposure to fentanyl, two-
thirds tested positive for fentanyl via urine-testing (10). Similarly, a recent drug-testing study in 
Canada found that 91% of heroin samples submitted to a testing service tested positive for 
fentanyl via testing strips (26). Our results suggest that hair testing may prove beneficial in 
helping detect past exposure to specific compounds. Another benefit of hair testing is that past 
exposure (e.g., weeks or months prior to testing) can be detected and this information may be 




 While over a quarter of participants reported having ever knowingly using fentanyl, 
large portions of participants reported that they would engage in various behavior changes if 
learning their hair had tested positive for fentanyl. Trials examining actual behavior changes in 
response to positive (and negative) results are needed. While more research is in fact needed, 
results indicate desire of individuals who use heroin to know whether they have been exposed 
to fentanyl and many report willingness to engage in behavioral change if provided with such 
results.  
This study has limitations. The study focused on a relatively small sample of inpatients in 
a detoxification program that use heroin so results may not be fully generalizable. The study 
was underpowered to detect potential differences within such a small sample, but this study 
was conducted as a pilot to inform larger studies. Longitudinal studies are also needed to assess 
actual changes in behavior as self-reported intention to engage in a behavior does not 
necessarily translate into action. Mixed methods research in particular is needed to further 
investigate risk factors not only for ever being unintentionally exposed to fentanyl, but for 
exposure to multiple analogs—particularly of analogs that are much more potent and 
dangerous than fentanyl. Another limitation is that the questions about beliefs and concerns 
about fentanyl use, and about reactions if learned their hair tested positive, were not 
previously validated measures. It is also unknown to what extent these individuals already 
engaged in such harm reduction behaviors. Hair testing typically cannot reliably detect very 
recent exposure to drugs (e.g., within a few days to a week) as detection depends on rate of 
hair growth. Shorter hair samples limited our ability to detect less-recent exposure so shorter 
samples were more likely to lead to false-negatives with regard to exposure detection. Finally, it 
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is possible that other opioids were present in hair samples that were not capable of being 
tested.  
In conclusion, almost all participants in this sample tested positive for fentanyl and 
many others also tested positive for its analogs. Individuals who use heroin, clinicians, and 
public health experts alike can benefit from having such information on exposure to these 
highly potent and dangerous compounds. While hair testing cannot provide immediate results 
like urine test strips, it can provide clinicians and medical staff with extensive exposure histories 
of various compounds and this information can inform surveillance, prevention, and harm 
reduction. Thus, test results can be provided through person-level individual feedback or 
through relaying such information to overall populations at risk. Results suggest hair testing can 
provide valuable information to clinicians and epidemiologists in a time of the worsening opioid 
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